Cullinan Therapeutics Income Statement (2020-2026) | CGEM

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
Operating items
Research & Development (Quarter)
11.78M12.68M20.88M24.54M26.41M19.68M21.32M52.10M27.39M33.82M34.85M30.65M36.26M35.51M40.49M41.46M61.03M41.97M42.95M42.12M
Selling, General & Administrative (Quarter)
4.83M5.70M13.47M8.12M10.70M10.09M11.29M10.66M10.21M10.98M10.64M12.34M13.77M13.35M14.56M13.54M14.77M13.63M12.31M11.57M
Operating Expenses (Quarter)
16.60M18.38M34.35M32.66M37.11M29.77M32.61M62.76M37.60M44.80M45.48M42.99M50.03M48.85M55.05M55.00M75.80M55.59M55.26M53.70M
Operating Income (Quarter)
-16.60M-18.38M-34.35M-32.66M239.68M-29.77M-32.61M-62.76M-37.60M-45.24M-45.48M-42.99M-50.03M-48.85M-55.05M-55.00M-75.80M-55.59M-55.26M-53.70M
EBIT (Quarter)
-16.60M-18.38M-34.35M-32.66M239.68M-29.77M-32.61M-62.76M-37.60M-45.24M-45.48M-42.99M-50.03M-48.85M-55.05M-55.00M-75.80M-55.59M-55.26M-53.70M
Non-operating items
Interest & Investment Income (Quarter)
0.17M0.12M0.14M0.20M0.70M2.35M3.36M4.51M5.32M5.88M5.92M5.69M8.07M8.38M7.51M6.58M5.92M5.09M4.62M4.10M
Other Non Operating Income (Quarter)
-0.01M-0.00M0.00M-0.24M0.30M0.11M0.07M0.18M-0.12M-0.04M-0.07M-0.09M0.01M-0.09M-0.18M-0.11M-0.07M-0.06M
Net income details
EBT (Quarter)
-16.44M-18.26M-34.21M-32.46M240.13M-27.41M-28.95M-58.14M-32.21M-39.18M-39.69M-40.86M-45.00M-40.71M-178.47M-48.71M-70.05M-51.74M-50.65M-52.35M
Tax Provisions (Quarter)
-19.57M66.07M-2.52M-1.90M14.10M
Profit After Tax (Quarter)
-16.44M-17.35M-34.21M-12.89M174.06M-24.80M-28.80M-58.14M-32.21M-39.18M-25.56M-37.34M-42.03M-40.56M-47.65M-48.50M-70.06M-50.61M-50.71M-50.55M
Income from Non-Controlling Interests (Quarter)
-0.80M-0.91M-1.69M-2.30M-0.50M-0.09M-0.31M1.36M-0.38M-1.76M-0.20M-0.14M1.45M0.64M0.10M-1.11M-0.89M
Income from Continuing Operations (Quarter)
-16.44M-18.26M-34.21M-12.89M174.06M-24.89M-27.05M-58.14M-32.21M-39.18M-53.78M-40.86M-45.00M-40.71M-178.47M-48.71M-70.05M-51.74M-50.65M-52.35M
Consolidated Net Income (Quarter)
-16.44M-18.26M-34.21M-12.89M174.06M-24.89M-27.05M-58.14M-32.21M-39.18M-53.78M-40.86M-45.00M-40.71M-178.47M-48.71M-70.05M-51.74M-50.65M-52.35M
Income towards Parent Company (Quarter)
-16.44M-18.26M-34.21M-12.89M174.06M-24.89M-27.05M-58.14M-32.21M-39.18M-53.78M-40.86M-45.00M-40.71M-178.47M-48.71M-70.05M-51.74M-50.65M-52.35M
Net Income towards Common Stockholders (Quarter)
-16.44M-18.26M-34.21M-12.89M174.06M-24.89M-27.05M-58.14M-32.21M-39.18M-53.78M-40.86M-45.00M-40.71M-178.47M-48.71M-70.05M-51.74M-50.65M-52.35M
Additional items
EPS (Basic) (Quarter)
-0.38-0.42-0.79-0.293.88-0.55-0.60-1.43-0.81-0.92-1.29-0.95-0.82-0.70-11.32-2.49-3.38-2.47-2.41-2.45
EPS (Diluted) (Quarter)
-0.38-0.42-0.79-0.293.75-0.55-0.58-1.43-0.81-0.92-1.29-0.95-0.82-0.70-3.06-0.83-1.20-0.89-0.87-0.90
Shares Outstanding (Quarter)
43.30M43.44M43.08M44.43M44.87M45.61M45.16M40.68M39.95M42.73M41.55M43.01M55.05M58.34M15.76M19.55M20.70M20.97M21.06M21.33M
Shares Outstanding (Diluted) (Quarter)
43.30M43.44M43.08M44.43M46.38M45.61M46.64M40.68M39.95M42.73M41.55M43.01M55.05M58.34M58.34M58.34M58.34M58.34M58.34M58.34M
EBITDA (Quarter)
-16.60M-18.38M-34.35M-32.66M239.68M-29.77M-32.61M-62.76M-37.60M-45.24M-45.48M-42.99M-50.03M-48.85M-55.05M-55.00M-75.80M-55.59M-55.26M-53.70M
Interest Expenses (Quarter)
312.85M1.69M44.55M3.13M3.63M5.76M46.77M5.54M5.08M1.06M87.37M3.56M3.05M0.24M130.94M0.29M0.18M1.24M0.01M2.75M
Tax Rate (Quarter)
60.2827.519.206.56-35.53